Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Офтальмология / Английские материалы / Retinal Degenerative Diseases Laboratory and Therapeutic Investigations_Anderson_2008.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
10.55 Mб
Скачать

488

S.J. Fliesler

proteins modifications are known to compromise protein structure and function and have been implicated in various diseases that involve oxidative stress (reviewed in Negre-Salvayre et al. 2008). Curiously, rhodopsin (the overwhelmingly dominant ROS membrane protein) somehow evades such modifications (Fliesler et al. 2006). In addition, initial DNA microarray analysis has revealed that hundreds of genes are differentially expressed in retinas of SLOS rats, compared to age-matched controls (Siddiqui et al. 2007, 2008), with the number and types of differentially expressed genes correlating well with the time course of retinal degeneration. Notably, among the affected gene families are those associated with oxidative stress and regulation of cell death.

Given the evidence for oxidation of both lipids and proteins in the SLOS rat model, in addition to the expected sterol pathway modifications, we suggest that future development of therapeutic interventions for clinical management of SLOS patients should include antioxidants in addition to cholesterol supplementation. Determining which antioxidants to use, the dosage, timing, and formulation with cholesterol will be challenging. The SLOS rat model described herein offers an excellent test system with which to evaluate the efficacy of these various factors in advance of randomized clinical testing in human patients.

Acknowledgments The author thanks the following collaborators for their significant contributions to the studies briefly summarized herein: Robert E. Anderson, Kathleen Boesze-Battaglia, R. Steven Brush, Deborah Ferrington, David Ford, Rebecca Kapphahn, Drake Mitchell, Barbara Nagel, Neal Peachey, Michael Richards, Akbar Siddiqui, and Dana Vaughan. This work was supported, in part, by U.S.P.H.S. (NEI/NIH) grant EY007361, by a departmental Challenge Grant and a Senior Scientific Investigator Award from Research to Prevent Blindness, and by a grant from the March of Dimes.

References

Bloch K (1989) Sterol structure and function. Steroids 53(3–5):261–270

Boesze-Battaglia K, Damek-Poprawa M, Mitchell DC et al (2008) Alteration of retinal rod outer segment membrane fluidity in a rat model of Smith-Lemli-Opitz syndrome. J Lipid Res 49(7):1488–1499

Correa-Cerro LS, Porter FD (2005) 3beta-Hydroxysterol delta7-reductase and the Smith-Lemli- Opitz syndrome. Mol Genet Metab 84(2):112–126

Demel RA, DeKruyff B (1976) The function of sterols in membranes. Biochim Biophys Acta 457(2):109–132

Dvornik D, Kraml M, Dubuc J et al (1963) A novel mode of inhibition of cholesterol biosynthesis. J Am Chem Soc 85:3309

Elias ER, Hansen RM, Irons M et al (2003) Rod photoreceptor responses in children with Smith- Lemli-Opitz syndrome. Arch Ophthalmol 121(12):1738–1743

Fliesler SJ (2002) Effects of cholesterol biosynthesis inhibitors on retinal development, structure, and function. In: Fliesler SJ (ed) Sterols and oxysterols: chemistry, biology and pathobiology. Research Signpost, Kerala, India, 77–109

Fliesler SJ, Kapphahn BJ, Ferrington DA et al (2006). Rhodopsin resists oxidative modification by PUFA-derived aldehydes and nitrosylation during lightand metabolically-induced retinal degenerations. Abstract, Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, May, 2006 [on CD-ROM]

55 Retinal Degeneration in a Rat Model of SLOS

489

Fliesler SJ, Keller RK (1997) Isoprenoid metabolism in the vertebrate retina. Int J Biochem Cell Biol 29(6):877–894

Fliesler SJ, Peachey NS, Richards MJ et al (2004) Retinal degeneration in a rodent model of Smith- Lemli-Opitz syndrome: electrophysiological, biochemical, and morphological features. Arch Ophthalmol 122(8):1190–2000

Fliesler SJ, Richards MJ, Miller C-Y, Peachey NS (1999) Marked alteration of sterol metabolism and composition without compromising retinal development or function. Invest Ophthalmol Vis Sci 40:1792–1801

Fliesler SJ, Vaughan DK, Jenewein EC et al (2007) Partial rescue of retinal function and sterol steady-state in a rat model of Smith-Lemli-Opitz syndrome. Pediatr Res 61:273–278

Ford DA, Monda JK, Brush RS et al (2008) Lipidomic analysis of the retina in a rat model of Smith- Lemli-Opitz syndrome: alterations in docosahexaenoic acid content of phospholipid molecular species. Neurochem 105(3):1032–1047

Givner ML, Dvornik D (1965) Agents affecting lipid metabolism – XV. Biochemical studies with the cholesterol synthesis inhibitor AY-9944 in young and mature rats. Biochem Pharmacol 14:611–619

Gofflot F (2002) Defects in cholesterol biosynthesis and abnormal embryonic development. In: Fliesler SJ (ed) Sterols and oxysterols: chemistry, biology, and pathobiology. Research Signpost, Trivandrum, India, 47–76

Kolf-Clauw M, Chevy F, Wolf C et al (1996) Inhibition of 7-dehydrocholesterol reductase by the teratogen AY9944: a rat model for Smith-Lemli-Opitz syndrome. Teratology 54:115–125 Negre-Salvayre A, Coatrieux C, Inggueneau C, Salvayre R (2008) Advanced lipid peroxidation end

products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 53(1):6–20

Porter FD (2003) Human malformation syndromes due to inborn errors of cholesterol synthesis. Curr Opin Pediatr 15:607–613

Porter FD (2008) Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 16(5):535–541

Richards MJ, Nagel BA, Fliesler SJ (2006) Lipid hydroperoxide formation in the retina: correlation with retinal degeneration and light damage in a rat model of Smith-Lemli-Opitz syndrome. Exp Eye Res 82:538–541

Siddiqui AM, Richards MJ, Fliesler SJ (2007) Global differential and temporal transcriptional profiling of retinas from AY9944-treated (SLOS) vs. control rats. Abstract, Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, May, 2007 [on CD-ROM]

Siddiqui AM, Wassif CA, Porter FD et al (2008) A systems-level approach to temporal transcriptional profiling of retinas in a rat model of Smith-Lemli-Opitz syndrome. Abstract, Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, May, 2008 [on CD-ROM]

Smith DW, Lemmli L, Opitz JM (1964) A newly recognized syndrome of multiple congenital anomalies. J Pediatr 64:210–217

Tint GS, Salen G, Batta AK et al (1995) Correlation of severity and outcome with plasma sterol levels in variants of the Smith-Lemli-Opitz syndrome. J Pediatr 127(1):82–87

Vaughan DK, Peachey NS, Richards MJ et al (2006) Light-induced exacerbation of retinal degeneration in a rat model of Smith-Lemli-Opitz syndrome. Exp Eye Res 82:496–504

Xu G, Salen G, Shefer S et al (1995) Reproducing abnormal cholesterol biosynthesis as seen in the Smith-Lemli-Opitz syndrome by inhibiting the conversion of 7-dehydro-cholesterol to cholesterol in rats. J Clin Invest 95:76–81

Yeagle PL (1985) Cholesterol and the cell membrane. Biochim Biophys Acta 822(3–4):267–287 Yu H, Patel SB (2005) Recent insights into the Smith-Lemli-Opitz syndrome. Clin Genet

68(5):383–391